StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Deven Choksey, DRChoksey

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byDeven Choksey, DRChokseyHorizon: NA (inferred 1 year)25 Jul 2025via Institutional / Brokerage Research

Entry₹971.25Inferred
Target₹1,069
Total upside +10.06% (call closed)
Stop lossNot given
Exit₹1,06920 May 2026, 12:05 pm
Target hit+10.06%0.00%upside left
Follow Deven Choksey for new calls(73% target hit, 66 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 7 active Long-term calls on ZYDUSLIFESee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:35 pm IST
7 supporting2 neutral2 opposing
Supports the BUY call (7)

Promoters intend to participate in the company's buyback program.

BSE · Company Update·19 May · today

(opens in new tab)

Promoters intend to participate in the company's buyback program.

BSE · Company Update·19 May · today

(opens in new tab)

Zydus Lifesciences Ltd has acquired shares of Assertio Holdings Inc., indicating a strategic expansion.

BSE · Company Update·13 May · 6d ago

(opens in new tab)

Zydus Lifesciences Ltd has acquired shares of FBC Medical, France.

BSE · Company Update·1 May · 3w ago

(opens in new tab)

Zydus Lifesciences Ltd has acquired shares of Aptitude Orthopedie, France.

BSE · Company Update·1 May · 3w ago

(opens in new tab)
Neutral / worth noting (2)

Zydus Lifesciences Limited's Board of Directors has approved a proposal to buy back up to 95,65,217 equity shares at INR 1,150 per share, for an aggregate amount not exceeding INR 1100 crore. The buyb

NSE · Outcome of Board Meeting·19 May · today

(opens in new tab)

Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

NSE · Outcome of Board Meeting·19 May · today

(opens in new tab)
Weighs against the BUY call (2)

Zydus Lifesciences Ltd received a demand order-in-appeal from the Appellate Authority, Central Goods and Services Tax Appeals Commissionerate, Chandigarh.

BSE · Company Update·13 May · 6d ago

(opens in new tab)

Zydus VTEC Limited, a subsidiary of Zydus Lifesciences, has received a Demand Order-In-Original from the Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate.

BSE · Company Update·5 May · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Deven Choksey, DRChoksey

Every call and its outcome